Historically, cryopreservation has struggled with two lethal hurdles: cellular damage caused by ice crystal formation, and structural cracking due to thermal stress. The system developed by Until Labs solves this by achieving stable vitrification, transforming biological liquids into an ice-free glass state. Through an engineered workflow that manages precise cooling rates, tailored cryoprotective solutions, and localized pressure controls, the system ensures high cell viability upon thawing, offering a functional pause button for living tissues.

Why the Invention is Deeply Innovative

The true innovation of this patent lies in its holistic, multi-dimensional engineering approach to biological preservation. Rather than relying on simple chemical formulas, the system controls three critical elements simultaneously: thermodynamic homogeneity, precise temperature rates, and dynamic pressure regulation. The apparatus includes a customized container paired with a pressurization system that pushes cryoprotective agents deep into tissues, drastically enhancing diffusion rates. Additionally, a thermally conductive holder maintains absolute uniformity across the entire specimen, preventing the microscopic thermal gradients that typically cause complex organs to crack.

Furthermore, the patent introduces the integration of specialized nanoparticles within the cryoprotective solution. When it is time to reverse the preservation, these nanoparticles work in tandem with rapid volumetric rewarming hardware, such as an alternating magnetic field system. This configuration allows a full-sized organ to heat uniformly from the inside out, completely bypassing the classic challenge where the surface thaws faster than the interior. This uniform rewarming prevents recrystallization and thermal shock, ensuring the organ remains fully viable and functional.

Earning California’s Patent of the Month for June 2026

Winning California’s Patent of the Month for June 2026 highlights the immense real-world value of this technology. California is a global center for biotech leadership, and this selection underscores a massive leap forward in medical technology. The evaluation panel recognized the patent for its potential to solve the modern organ shortage crisis. By successfully extending the viability window of donor organs from a few critical hours to multiple weeks or months, this technology eliminates the logistical bottlenecks that cause thousands of donated organs to be discarded annually, saving countless lives in the process.

Practical Applications and Eligibility for the US R&D Tax Credit

The practical development, optimization, and testing of the methods outlined in this patent represent eligible activities for the United States Research and Development (R&D) Tax Credit under Internal Revenue Code Section 41. To qualify, a company’s activities must satisfy a strict four-part test: the work must be technological in nature, target the elimination of technical uncertainty, involve a systematic process of experimentation, and focus on creating a new or improved product function. In practice, evaluating different concentrations of cryoprotective agents to minimize toxicity, configuring the flow rates of the automated pressurization system, and engineering specific alternating magnetic field frequencies to achieve uniform volumetric heating all count as qualified research expenses. By meticulously tracking engineering hours, prototyping materials, and biological viability trial data, the enterprise can secure substantial R&D tax credits to offset the substantial operational costs of bringing this life-saving cryopreservation platform to commercial reality.